Aim: To determine whether long-term treatment with oral betablocker (BB) therapy after myocardial infarction (MI) in patient with no heart failure reduces the composite outcome of recurrent non-fatal MI, all-cause mortality, revascularisation with percutaneous coronary intervention or coronary artery bypass graft, stroke, ventricular arrhythmia, cardiac arrest with successful resuscitation due to cardiac cause or heart failure.~Intervention: BB therapy versus no therapy.~Main Inclusion Criteria: Patient that have suffered a MI, both Non-ST elevation MI and ST elevation MI and can be randomized within 14 days of MI with no signs of heart failure and a left ventricular ejection fraction>40%.~Main Exclusion Criteria: Any indication or contraindication for BB treatment other than secondary prevention according to the treating cardiologist~Primary study endpoint: The composite of all-cause mortality, recurrent non-fatal MI, revascularisation with PCI or CABG, stroke, ventricular arrhythmia, cardiac arrest with successful resuscitation due to cardiac cause or heart failure.~Sample Size: A total of approximately 3570 patients will be recruited and randomized 1:1 to BB treatment (type and dosage according to treating physician) or no BB treatment. Treatment must be initiated within 14 days of MI.~Location: All departments of cardiology in Denmark are invited to participate. All patients admitted to hospital for MI will be screened for in- and exclusion criteria and contacted if eligible.~Treatment Duration: Estimated (non) treatment duration of 6 months-6 years.~Follow-up: Patients will be followed from the randomization date until end of follow-up with respect to the primary and most secondary endpoints.~Assessment of primary study and safety end points: Serious adverse events (SAE) will be monitored through patient reported hospital admission by surveys every 3 months combined with local follow-up on patients that do not respond to surveys~Intervention and dosage of BB treatment: The intervention will be active treatment with BB, type and dosage according to treating cardiologist choice and control will be standard care (without BB treatment). The treating cardiologist is recommended to use the highest dose deemed tolerable for the patient at the time of randomization. Dosage, adherence and cross-over will be monitored through linkage to the Danish Register of Medical Product Statistics.~Sample size considerations: Assuming a hazard ratio of 1.2 for the non-treated group compared to the treated the DANBLOCK trial has 80% power to detect this effect with an accumulation of 900 events of the primary endpoint. With approximately 3570 patients randomized the investigators expect to reach 900 events within the study period.~Statistical Analysis: Intention-to-treat analysis will be carried out. Additionally, a secondary per-protocol analysis will be performed, where compliant BB-users patients are considered exposed during follow-up. Outcome analysis will be assessed by using cumulative incidence and Cox-regressions.~Data Safety Monitoring Board (DSMB): This committee consisting of two senior cardiologists and one trial-science statistician will overview safety and will have access to unblinded data. They will formally review the accumulating data every 6 months throughout the study period to ensure there is no avoidable increased harm to patients. The DSMB may recommend trial termination due to excess risk associated with no treatment with BB.~Recruitment: All patients admitted to hospital for MI will be screened for in- and exclusion criteria and contacted if eligible. Logistics of identifying and contacting the patients will be organized locally; some hospitals will randomize patients before discharge, others will contact patients after discharge. Patients will be randomized 1:1.~Publication policy: On study completion the results will be submitted for publication in an international medical journal. The results of this study will also be submitted to the Competent Authority and the Ethics Committee according to EU and Danish regulations.
To determine whether long-term treatment with oral betablocker therapy after myocardial infarction in patient with no heart failure reduces the composite outcome of recurrent non-fatal MI, all-cause mortality, revascularisation with percutaneous coronary intervention or coronary artery bypass graft, stroke, ventricular arrhythmia, cardiac arrest with successful resuscitation or heart failure.